Forty skin interventions, ranked.

The answer, first

Three uncomfortable facts

Three facts that reorder the whole field before a single intervention is graded.

One. The most-cited copper peptide trial in existence is negative. Miller 2006 randomised patients after CO2 laser resurfacing to a regimen with or without GHK-Cu. Blinded evaluators and computer analysis found no significant difference in erythema, wrinkles or skin quality. The only endpoint that favoured copper peptide was the patient satisfaction questionnaire.

The authors' own words: "Objective evaluation found no significant improvement in wrinkles or overall skin quality"¹. That study is roughly twenty years old and you have almost certainly never seen it quoted by anyone selling copper peptide.

Two. The trial the entire polynucleotide market descends from has been retracted. The 2014 phase III Rejuran crow's-feet study is flagged in the literature as a Retracted Publication, with its retraction notice published in the same journal in 2016².

A second randomised polynucleotide trial, this one in 218 participants, was also retracted, with notice published in 2026³. The surviving randomised evidence is a 27-patient split-face study in which polynucleotide did not significantly beat plain non-crosslinked hyaluronic acid on its primary aesthetic endpoints⁴.

Three. Oral collagen works in industry-funded trials and stops working in independent ones. Myung and Park pooled 23 randomised controlled trials and 1,474 participants in 2025.

Across all trials, collagen improved hydration, elasticity and wrinkles. Then they stratified. Trials not funded by pharmaceutical companies showed no effect on hydration, elasticity or wrinkles. High-quality trials showed no significant effect in any category.

Their conclusion, verbatim: "There is currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging"⁵.

That is the shape of this entire field. Not a shortage of studies. A shortage of studies that survive contact with a control group and a disclosed funding statement.

Prevention outranks repair. Sunscreen outranks the peptide.

How we graded

Five grades, two endpoint rules, and a bias toward biopsy over instrument readings.

Ranking is by strength of human evidence, not by how much we like the intervention. Effect size, mechanism plausibility and price are not part of the rank.

Where an intervention has strong evidence for something other than collagen, elastin or pores, it is ranked on the strength of that evidence and the mismatch is stated in the verdict column.

Two endpoint rules run underneath the grade. Biopsy beats instrument beats photograph beats self-report. And a vehicle arm is not optional — you will see below what happens to a 50% improvement when someone bothers to run one.

The top 40

Forty interventions on one ladder, each carrying the reason for its grade on the same line.

The elastin verdict

Three processes are sold as elastin repair. None of them has been shown to produce a cross-linked, load-bearing fibre in treated adult skin.

This is the section that will cost us advertisers if we had any.

Start with the biology. Elastin is effectively not replaced in adult tissue. The famous "74-year half-life" figure comes from a radiocarbon bomb-pulse study of human lung parenchyma, not skin — mean carbon residence time roughly 74 years, 95% confidence limits 40 to 174 years⁷⁵.

Any sentence claiming your skin elastin has a 74-year half-life is a citation error that has propagated through the aesthetics literature for decades.

The skin-specific measurement says something bleaker. Purified human skin elastin shows D-aspartate accumulation correlating with chronological age at r = 0.98 — the signature of a protein that is not turned over — and the authors attribute the racemisation rates, higher than earlier lung and aorta work, partly to "a significant in vivo degradation of elastin in skin"⁷⁶. Not replaced, and being degraded. A one-way account.

Now the trap. Three completely different things get sold to you as "elastin repair":

One: clearance of elastotic material. This is what most interventions actually do, and it shows up in the data as total elastin falling. Tretinoin reduced dermal elastin from 54.5% ± 3.68 to 43.4% ± 4.42 at six months, P=0.02⁷⁷. Microneedling significantly decreased total elastin⁸.

Ablative Er:YAG decreased elastin⁹. Combined microneedle and sublative RF produced a significant reduction in abnormal elastin⁷⁸. Falling elastin in photoaged skin is a good outcome. It is also the exact opposite of what "boosts your elastin" implies to a reader.

Two: microfibrillar scaffold restoration. Fibrillin-1 is the microfibril scaffold at the dermal-epidermal junction, and retinoids genuinely increase it — significantly, at protein and mRNA level⁷⁹.

Here is the caveat almost nobody prints: in that same experiment, 5% sodium lauryl sulfate, a pure irritant control, also significantly raised fibrillin-1. Tretinoin merely beat it. Some of what is sold as retinoid repair is a nonspecific irritation response.

Three: transcript and stain increases after wounding. Tropoelastin messenger RNA rising 28 days after a thermal wound is what a healing thermal wound does⁵¹. It is not evidence of a persisting functional fibre.

And here is the killer. LOXL1-null mice fail to deposit normal elastic fibres and develop loose skin, enlarged airspaces and organ prolapse — with concomitant tropoelastin accumulation⁸⁰.

Tropoelastin piles up precisely because it cannot be cross-linked and organised. So an intervention that raises tropoelastin or elastin immunostaining without demonstrating cross-linking has reproduced the LOXL1-null phenotype, not repair.

Desmosine and isodesmosine are the actual cross-links. No study we could verify has measured them in treated adult human skin. That missing endpoint is the single most quotable gap in the field.

What does the field's own commercial vanguard say? A 2026 paper on mRNA-lipid-nanoparticle elastin delivery states it flatly: "Although elastin has a long half-life, its production ceases in adults.

Damage to elastin caused by both intrinsic and extrinsic aging leads to an irreversible loss of skin elasticity"⁸¹. A clinically oriented review co-authored by the leading tropoelastin researcher puts it at review level: "few therapies are capable of repairing elastic fibers or substantially reorganizing the elastin/microfibril network"⁸².

The one human dataset we could verify that shows a rebuilt elastic network is Kligman 1985 — deep phenol peel, full-thickness specimens 1.5 to 20 years later, unpeeled skin from the same specimen as control, "fine elastic fibers formed a dense network"⁶⁰. Eleven women.

Nothing quantified. And the supporting human timeline is sobering: across 182 human scars, no elastic fibres were detected in any of the 116 scars less than three months old, with only progressive, focal, thin return after that⁸³. Nothing cosmetic operates on that timescale.

Be careful with the loudest counter-claim. The most aggressive "we reverse solar elastosis and build new elastin" position in the topical market rests on a retrospective pooled review and a five-patient split-face trial, with three of four authors on the 2026 paper employed by the manufacturer and all included trials funded by it⁸⁴.

Increased elastin staining is not proof of an assembled, cross-linked, load-bearing fibre. Treat it as a claim with histology attached.

Practical translation. Stop further damage — sunscreen has the only randomised evidence. Clear the debris — retinoids and energy devices demonstrably do this. Thicken the microfibril scaffold — retinoids, partly nonspecifically. That is the whole honest menu. Anyone selling you the fourth option is selling you the fantasy.

The peptide desk

Every peptide sold for skin, checked against the trials it is said to rest on.

This is our lane, so we will be blunt about it.

Across every systemic and injectable peptide marketed for skin, collagen or elastin, exactly one compound has a randomised controlled human trial with a measured skin endpoint — recombinant human growth hormone.

Twenty growth-hormone-deficient hypopituitary patients, randomised, double-blind, placebo-controlled, twelve months: PICP, the indicator of collagen type I synthesis, increased versus placebo, and ultrasound skin thickness rose significantly¹¹. That is replacement therapy correcting a pathological deficit.

It is not evidence that supraphysiologic growth hormone improves normal skin, and the best systematic review of growth hormone in the healthy elderly concludes it "cannot be recommended as an antiaging therapy," with significantly more soft tissue edema, arthralgias, carpal tunnel syndrome and gynecomastia⁸⁵.

For everything else, the number of randomised controlled human trials with a skin, collagen or elastin endpoint is zero.

Two contrasts worth holding onto. Afamelanotide — melanotan I — went through the full process: two randomised placebo-controlled trials published in the New England Journal of Medicine, FDA approval, a clinician-placed implant, and an indication in a rare photodermatosis⁹⁵.

Its cousin melanotan II has none of that. That gap is what "approved" actually costs to earn.

And bremelanotide is the tell on melanocortin skin claims: it is FDA-approved, and its melanocortin skin effect is focal hyperpigmentation listed as an unwanted adverse effect, not a benefit.

One more time, plainly, because the vendors will not say it: there is no injectable peptide with a randomised human trial showing it improves collagen, elastin or pore size. Not one.

Topical peptides

One biopsy exists across the entire retail category, and the molecules are mostly too large to cross the barrier intact.

We looked at fourteen. Here is the whole finding.

Across every heavily marketed INCI-named retail peptide, not one has biopsy-confirmed collagen or elastin data in living humans.

The only vehicle-controlled human study in this domain with a genuine skin-biopsy endpoint used an elastin-derived trifunctional peptide in 22 volunteers about to undergo facelift surgery, so the investigators could take real tissue at the operation — and what it reports is a change in the ratio between type I and type III collagens, not an absolute collagen gain¹².

Read that design and then look at what is on your shelf.

The penetration problem is mostly asserted, rarely demonstrated, and where it has been measured the results are unflattering. The 500-dalton rule is the benchmark⁶⁴. Palmitoyl pentapeptide-4 is 802 daltons; acetyl hexapeptide-8 is 887; palmitoyl tripeptide-1 is 579. All three are over.

GHK is 340 daltons and under the threshold, but its measured log D of roughly −2.4 makes it strongly hydrophilic and therefore poorly suited to crossing a lipid barrier.

Direct measurement found neither KTTKS nor palmitoyl-KTTKS reached the receptor solution through full-thickness skin at all⁶⁵. A dedicated permeation study of palmitoyl tripeptide-5 observed "almost no transdermal permeation."

The industry's own answer gives the game away: palmitoylation exists to improve skin penetration, which is a tacit admission the bare peptides do not get in.

Then there is the independent synthesis. The only systematic review and meta-analysis of randomised controlled trials in this space found a modest pooled wrinkle effect — mean difference 0.27, P=0.04 — and states that the benefit was "largely driven by oral polypeptides" at MD 1.5⁹⁶.

Effects on elasticity and density, the endpoints closest to actual collagen and elastin, were inconsistent.

The authors declare no commercial relationships, which makes them rare, and they close by asking for the histopathologic assessment this literature almost never performs.

Funding is pervasive and should be named every time. The founding Matrixyl trial: all authors Procter & Gamble. Tripeptide-10 citrulline's discovery paper: Lipotec. Hexapeptide-11: Arch Personal Care and Lonza.

Palmitoyl hexapeptide-12: Estée Lauder. The Syn-Ake serum study: entirely L'Oréal, and the formula also contained niacinamide and a polyhydroxy acid, either of which could account for the pore and smoothness numbers.

What a pore actually is

A pore is a follicular opening whose visible size tracks sebum output and the collagen supporting its wall. Neither is permanently changeable.

A visible facial pore is the surface opening of a pilosebaceous follicular ostium. It has no muscle and no sphincter. It does not open with steam or close with cold water. Those claims have no anatomical basis.

Three things drive visible size: high sebum excretion, decreased elasticity around the pore, and increased hair follicle volume, with recurrent acne, sex hormones and skincare regimen as modifiers¹⁰.

The sebum link is real but weaker than assumed, and the two best studies disagree. In 60 subjects, increased pore size was significantly associated with sebum output, sex and age, with correlations of r=0.47 in males and r=0.38 in females⁹⁷.

In 62 Thai women, casual sebum level and sebum excretion rate were 1.6 to 2.1 times higher in the self-described oily group — and mean pore area did not differ between groups and did not correlate with either sebum measure⁹⁸.

Even at its strongest, r=0.47 means sebum explains roughly a fifth of the variance.

The rest is structural. Skin with conspicuous pores shows a blunted rete ridge architecture around the ostium and increased keratin 16, suggesting hyperproliferation and a loss of peri-follicular support⁹⁹. A conspicuous pore is not simply a wide hole full of oil.

Measurement matters and most trials get it wrong. Visual grading of pores correlates most highly with pore volume from 3-D imaging, then 2-D area, and only slightly with counts of pores above 0.04 mm²¹⁰⁰. Most cosmetic trials report 2-D area or a clinician score.

And the durability question. No controlled trial with post-cessation follow-up establishes durable pore-size reduction. Retinoid pore scores are reported at 8 and 12 weeks.

Botulinum microdroplet effects are sustained "through 12 weeks" with maximum at 4 weeks¹⁰¹ — which is roughly the duration of botulinum effect, so nothing about permanence can be inferred.

Follicle size is substantially genetic. Sebum output is androgen-driven and rebounds when suppression stops. The honest claim available to any product or device is temporary improvement in pore appearance for as long as treatment continues.

The vehicle beats the active

In four trials the control arm moved almost as much as the active. Read the control bar first.

If you take one methodological habit from this report, take this one.

A 5% alpha-lipoic acid split-face trial reported a 50.8% decrease in skin roughness by laser profilometry — the most objective method used. On the placebo half of the same faces: 40.7%¹⁰². The drug-attributable difference is about ten percentage points, not fifty.

In the platelet-rich plasma histology study, collagen density improved 89% on the PRP side and 46% on the saline side⁶². In a growth-factor cream trial, the placebo arm improved about 10% on two roughness parameters¹⁰³.

In the glycolic acid trial, 40% of vehicle patients improved at least one photodamage grade⁴⁴. In the broadband-light pore trial, the untreated side improved too, which is why the between-arm P value was .606⁷³.

Any before-and-after study without a vehicle arm is uninterpretable. That covers most of the topical peptide literature, most of the exosome literature, the widely circulated "sunscreen reverses photodamage" study — 32 subjects, no control group, industry-conducted¹⁰⁴ — and the 61-to-100% pore and wrinkle reduction figures from a 1996 topical estrogen study that compared two active hormones against each other with no vehicle arm at all¹⁰⁵.

The community file

Our August 2026 sweep of the skin-peptide communities found a real, recurring satisfaction record. Its shape matches this ranking almost exactly.

The dominant topical report is glow and plumpness, sometimes within days and occasionally overnight — and the speed is the tell. Hydration and surface optics move in hours; collagen remodeling moves in months.

The fastest and most enthusiastic reports in the sweep are evidence about vehicles and humectants, which is precisely what the vehicle section above predicts.

The sweep's most useful anecdote came with its own control: a user whose under-eye area and lip lines reportedly improved while the neck did not — more informative than a before-and-after, still proof of nothing.

Injectable skin-peptide reports place texture and hair changes at weeks to months, and carry the worst attribution in the entire sweep: blends, concurrent topicals, planned procedures and uncertain product identity run through nearly every account. Repurchase loyalty is high on both routes — and loyalty measures satisfaction, not biology.

The full route-by-route record lives in the GHK-Cu report's community file, and the method for reading records like this is the community evidence framework. What the community file cannot do is move a single row of the ranking above — that would take the vehicle-controlled trials this field keeps not running.

What missed the 40

Interventions excluded, and the specific bar each one failed.

Ranked out, not because they are necessarily useless, but because the human evidence is not there yet:

Topicals: bakuchiol [one 44-person active-comparator trial, no vehicle arm, ingredient-supplier affiliation on the mechanistic paper], adapalene [one trial, histologic differences explicitly non-significant], retinyl esters [the randomised trial found no significant change in procollagen I], trifarotene [mice and keratinocytes only], topical growth factors [33 studies, only 9 randomised], topical exosomes [no vehicle arm anywhere, and FDA states there are no approved exosome products], topical hyaluronic acid, ceramides [excellent barrier evidence, no matrix evidence], vitamin C derivatives, DMAE [the mechanism paper attributes the firming effect to cell vacuolization], caffeine [11 subjects, water as comparator].

Procedures and injectables: PDO threads [the collagen claim rests on pig studies; FDA cleared them for mechanical mid-face suspension, not biostimulation], dermal micro-coring, monopolar RF [collagen density rose from 0.736 to 0.773, statistically significant and clinically trivial; the elastic fibre change was explicitly not significant], picosecond fractional laser, microdermabrasion [worked only with a coarse handpiece; the medium-grit arm was flat negative], dermabrasion.

Oral and lifestyle: oral zinc, choline-stabilised orthosilicic acid, Polypodium leucotomos [good acute photoprotection, no matrix endpoint], oral vitamin C monotherapy, cold exposure [no human study of any design exists], facial exercise, sleep position [the single citation is a review by the inventor of a wrinkle pillow], weight cycling [complete evidence vacuum], alcohol [two studies pointing in opposite directions], dietary protein [a genuine gap, not a search failure], cleansing frequency [the one randomised trial found washing once daily was worse than twice, and four times was no better than twice].

One correction on a claim you will see constantly: "Ozempic face" is a fat compartment phenomenon, not a collagen one.

Radiographic imaging shows roughly 7% midfacial volume loss per 10 kg of total weight lost, with weight loss correlating with superficial volume loss but not deep¹⁰⁶. Nobody has measured dermal collagen, elastin or skin thickness in these patients. There is no evidence GLP-1 drugs damage the dermal matrix.

The honest stack

What the evidence supports, in the order it supports it.

Not a protocol. A description of where the evidence actually sits, in descending order of how much you can trust it.

Tier one — do this or nothing else matters. Daily broad-spectrum sunscreen. It is the only intervention on this list with a multi-year randomised trial showing slowed skin aging, and there is a mechanistic reason it outranks everything you can swallow.

The best-supported model of dermal aging is a self-perpetuating loop: fragmented collagen means fibroblasts lose mechanical tension, collapsed fibroblasts synthesise less — type I procollagen production falls from 82 ± 16 ng/ml in donors aged 18 to 29 to 56 ± 8 ng/ml in donors over 80¹⁰⁷ — and elevated MMP-1 fragments more collagen¹⁰⁸.

On that model, preventing fragmentation matters more than adding raw material. Which is precisely why sunscreen beats every supplement in the table above.

Tier two — the one topical with biopsy evidence. Tretinoin, if you can tolerate it. Retinol and retinaldehyde are legitimate step-downs with real but thinner data. Retinyl esters are not.

Tier three — if pores are the complaint. Niacinamide has the only randomised vehicle-controlled trial with a pore-count endpoint. Beyond that you are into prescription sebum suppression, and you should understand you are buying temporary appearance, not permanent anatomy.

Tier four — procedures, chosen by skin type. Fractional ablative CO2 has the best collagen data and the worst pigmentary risk. Microneedling has weaker collagen data and the best pigmentary safety record. That trade is the whole decision for anyone with Fitzpatrick IV or above.

Things to deprioritise on the evidence: oral collagen, topical peptides, platelet-rich plasma, intense pulsed light for structure, polynucleotides, and every injectable research peptide sold for skin.

We sell nothing, and the report above links to no vendor. Everything in it is descriptive of published protocols, not a recommendation to use any of it.

FAQ

References

All identifiers below were retrieved and verified. Where a claim could not be confirmed against a primary source, it has been softened or omitted rather than cited.

1. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171
2. Pak CS, et al. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial. J Korean Med Sci. 2014. PMID 25473210 — RETRACTED; notice J Korean Med Sci. 2016;31:330
3. A randomized, participant- and evaluator-blinded, matched-pair, prospective study. J Cosmet Dermatol. 2025. PMID 39313949 — RETRACTED; notice J Cosmet Dermatol. 2026;25:e70794
4. Lee SK, et al. Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation. J Dermatolog Treat. 2022. PMID 32248707
5. Myung SK, Park SJ. Effects of Collagen Supplements on Skin Aging: SR and meta-analysis of RCTs. Am J Med. 2025;138:1264-1277. PMID 40324552
6. Hughes MC, et al. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med. 2013;158:781-90. PMID 23732711
7. Boyd AS, et al. The effects of chronic sunscreen use on the histologic changes of dermatoheliosis. J Am Acad Dermatol. 1995;33:941-6. PMID 7490363
8. El-Domyati M, et al. Multiple microneedling sessions for minimally invasive facial rejuvenation. Int J Dermatol. 2015. PMID 26096653
9. El-Domyati M, et al. Fractional versus ablative erbium:YAG laser resurfacing. J Am Acad Dermatol. 2013. PMID 23110966
10. Lee SJ, et al. Facial Pores: Definition, Causes, and Treatment Options. Dermatol Surg. 2016;42:277-85. PMID 26918966
11. Growth hormone substitution in growth hormone-deficient adults: effects on collagen type I synthesis and skin thickness. Exp Clin Endocrinol Diabetes. 1996. PMID 8886750
12. Abraham J, et al. Clinical validation of an elastin-derived trifunctional peptide for skin regeneration. Am J Transl Res. 2023;15:4620-4628. PMID 37560234
13. Griffiths CE, et al. Restoration of collagen formation in photodamaged human skin by tretinoin. N Engl J Med. 1993. PMID 8336752
14. Tretinoin for Photodamaged Facial Skin: SR and meta-analysis of RCTs. Dermatol Pract Concept. 2025. PMID 41236273
15. Phillips TJ, et al. Efficacy of 0.1% tazarotene cream for the treatment of photodamage. Arch Dermatol. 2002. PMID 12437455
16. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology. 1998. PMID 9557249
17. Bagatin E, et al. A randomized and controlled trial about the use of oral isotretinoin for photoaging. Int J Dermatol. 2010. PMID 20465648
18. Bagatin E, et al. Low-dose oral isotretinoin versus topical retinoic acid for photoaging. Int J Dermatol. 2014. PMID 24168514
19. Rahman E, et al. Intradermal Botulinum Toxin A on Skin Quality and Facial Rejuvenation: SR and meta-analysis. Plast Reconstr Surg Glob Open. 2024. PMID 39185380
20. Efficacy of Incobotulinumtoxin A on Maskne: prospective, placebo-controlled, double-blind. J Cosmet Dermatol. 2025. PMID 40847901
21. Chiu PC, et al. The clinical anti-aging effects of topical kinetin and niacinamide in Asians. J Cosmet Dermatol. 2007. PMID 18047609
22. Draelos ZD, et al. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006. PMID 16766489
23. Knuutinen A, et al. Smoking affects collagen synthesis and extracellular matrix turnover in human skin. Br J Dermatol. 2002. PMID 11966688
24. Orringer JS, et al. Direct quantitative comparison of molecular responses to fractionated and fully ablative resurfacing. Dermatol Surg. 2012. PMID 22805255
25. Argobi Y, et al. Fractional CO2 Laser Versus Micro Needling Radiofrequency for Post Acne Scarring: meta-analysis of RCTs. J Cosmet Dermatol. 2026. PMID 41821146
26. Chan HH, et al. Fractional ablative carbon dioxide laser resurfacing in Asians. Lasers Surg Med. 2010. PMID 20976801
27. Shen S, et al. Microneedling Monotherapy for Acne Scar: SR and meta-analysis of RCTs. Aesthetic Plast Surg. 2022. PMID 35426044
28. Santer M, et al. Effectiveness of spironolactone for women with acne vulgaris [SAFA]. BMJ. 2023;381:e074349. PMID 37192767
29. Narins RS, et al. A randomized study of injectable poly-L-lactic acid versus human-based collagen implant. J Am Acad Dermatol. 2010. PMID 20159311
30. Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013. PMID 23464798
31. Creidi P, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998. PMID 9843009
32. Humbert PG, et al. Topical ascorbic acid on photoaged skin: double-blind study vs placebo. Exp Dermatol. 2003. PMID 12823436
33. Fitzpatrick RE, Rostan EF. Double-blind, half-face study comparing topical vitamin C and vehicle. Dermatol Surg. 2002. PMID 11896774
34. Amiri M, et al. MFU-V Effectiveness and Safety: SR and Meta-Analysis. Aesthet Surg J. 2025. PMID 39540440
35. Alam M, et al. Ultrasound tightening of facial and neck skin: rater-blinded prospective cohort study. J Am Acad Dermatol. 2010. PMID 20115948
36. Marquardt K, et al. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin Within the Skin. J Cosmet Dermatol. 2025. PMID 39545626
37. Kwon HH, et al. Clinical and histological effect of a low glycaemic load diet in acne vulgaris. Acta Derm Venereol. 2012. PMID 22678562
38. Smith RN, et al. A low-glycemic-load diet improves symptoms in acne vulgaris patients: RCT. Am J Clin Nutr. 2007. PMID 17616769
39. Kafi R, et al. Improvement of naturally aged skin with vitamin A [retinol]. Arch Dermatol. 2007. PMID 17515510
40. Shao Y, et al. Molecular basis of retinol anti-ageing properties in naturally aged human skin in vivo. Int J Cosmet Sci. 2017. PMID 27261203
41. Brincat M, et al. Sex hormones and skin collagen content in postmenopausal women. Br Med J. 1983. PMID 6416400
42. Owen CM, et al. Effects of hormones on skin wrinkles and rigidity: four-year follow-up from the KEEPS ancillary study. Fertil Steril. 2016. PMID 27393520
43. Haapasaari KM, et al. Systemic therapy with estrogen or estrogen with progestin has no effect on skin collagen. Maturitas. 1997. PMID 9255750
44. Stiller MJ, et al. Topical 8% glycolic acid and 8% L-lactic acid creams: double-blind vehicle-controlled. Arch Dermatol. 1996. PMID 8651713
45. Piérard GE, et al. Comparative effects of retinoic acid, glycolic acid and a lipophilic derivative of salicylic acid. Dermatology. 1999. PMID 10449958
46. Wang F, et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections. Arch Dermatol. 2007. PMID 17309996
47. Cui X, et al. Rejuvenation of Aged Human Skin by Injection of Cross-linked Hyaluronic Acid. Plast Reconstr Surg. 2021. PMID 33347074
48. Yutskovskaya YA, Kogan EA. Improved Neocollagenesis and Skin Mechanical Properties After Injection of Diluted Calcium Hydroxylapatite. J Drugs Dermatol. 2017. PMID 28095536
49. Orringer JS, et al. Connective tissue remodeling induced by carbon dioxide laser resurfacing of photodamaged human skin. Arch Dermatol. 2004. PMID 15545540
50. Prado A, et al. Full-face carbon dioxide laser resurfacing: a 10-year follow-up descriptive study. Plast Reconstr Surg. 2008. PMID 18317147
51. Hantash BM, et al. Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. Lasers Surg Med. 2009. PMID 19143021
52. Kislevitz M, et al. Bipolar Fractional Radiofrequency Treatment of Suprapatellar Skin. Aesthet Surg J. 2021. PMID 33942050
53. Vierkötter A, et al. Airborne particle exposure and extrinsic skin aging. J Invest Dermatol. 2010. PMID 20664556
54. Margara A, et al. Hyaluronan Hybrid Cooperative Complexes Injection as a Biostimulation for Postobese Skin Laxity in the Arm. Aesthet Surg J Open Forum. 2024. PMID 38887212
55. Nelson BR, et al. Pilot histologic and ultrastructural study of the effects of medium-depth chemical facial peels on dermal collagen. J Am Acad Dermatol. 1995. PMID 7868719
56. Giese SY, et al. The effect of chemosurgical peels and dermabrasion on dermal elastic tissue. Plast Reconstr Surg. 1997. PMID 9252620
57. Nishikori S, et al. Resistance training rejuvenates aging skin. Sci Rep. 2023. PMID 37353523
58. Gubanova EI, et al. 12-month effects of stabilized hyaluronic acid gel compared with saline for rejuvenation of aging hands. J Drugs Dermatol. 2015. PMID 25738851
59. Oyetakin-White P, et al. Does poor sleep quality affect skin ageing? Clin Exp Dermatol. 2015. PMID 25266053
60. Kligman AM, et al. Long-term histologic follow-up of phenol face peels. Plast Reconstr Surg. 1985. PMID 3983273
61. Alam M, et al. Effect of Platelet-Rich Plasma Injection for Rejuvenation of Photoaged Facial Skin: RCT. JAMA Dermatol. 2018. PMID 30419125
62. Abuaf OK, et al. Histologic Evidence of New Collagen Formulation Using Platelet Rich Plasma. Ann Dermatol. 2016. PMID 27904271
63. Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. PMID 18492182
64. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000. PMID 10839713
65. Choi YL, et al. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides. Biomol Ther. 2014. PMID 25143811
66. Wang Y, et al. The anti-wrinkle efficacy of argireline: randomized, placebo-controlled study. Am J Clin Dermatol. 2013. PMID 23417317
67. Zdrada-Nowak J, et al. Acetyl Hexapeptide-8 in Cosmeceuticals: A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID 40565185
68. Zhou X, et al. SR and Meta-Analysis on the Effects of Astaxanthin on Human Skin Ageing. Nutrients. 2021. PMID 34578794
69. Yang Y, et al. Effectiveness of dietary supplements for skin photoaging in healthy adults: SR and meta-analysis. Front Med. 2025. PMID 40761858
70. Mortazavi M, et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts. 2024. PMID 39963574
71. Cheng L, et al. Injectable non-crosslinked hyaluronic acid: multicenter randomized assessor-blinded study. Clin Cosmet Investig Dermatol. 2026. PMID 41971651
72. Amin S, et al. Oral Hyaluronic Acid Supplement: Efficacy in Skin Hydration, Elasticity, and Wrinkle Depth Reduction. J Drugs Dermatol. 2025. PMID 40911749
73. Yu W, et al. A split-face randomized controlled trial of treatment with broadband light for enlarged facial pores. J Dermatolog Treat. 2021. PMID 31801404
74. El-Domyati M, et al. Intense pulsed light photorejuvenation: a histological and immunohistochemical evaluation. J Drugs Dermatol. 2011. PMID 22052303
75. Shapiro SD, et al. Marked longevity of human lung parenchymal elastic fibers. J Clin Invest. 1991;87:1828-34. PMID 2022748
76. Ritz-Timme S, Laumeier I, Collins MJ. Aspartic acid racemization: evidence for marked longevity of elastin in human skin. Br J Dermatol. 2003;149:951-9. PMID 14632798
77. El-Domyati M, et al. Effect of topical tretinoin on photoaged facial skin: histometric, immunohistochemical and ultrastructural study. J Cosmet Dermatol. 2004. PMID 17166106
78. El-Domyati M, et al. A New Approach with Combined Microneedle and Sublative Fractional Radiofrequency for Photoaging Management. Aesthetic Plast Surg. 2025. PMID 39414647
79. Watson RE, et al. A short-term screening protocol, using fibrillin-1 as a reporter molecule, for photoaging repair agents. J Invest Dermatol. 2001. PMID 11348454
80. Liu X, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet. 2004;36:178-82. PMID 14745449
81. Shi Y, et al. Elastin production by mRNA technology for rejuvenation of aged skin. J Control Release. 2026;395:115033. PMID 42155601
82. Baumann L, et al. Clinical Relevance of Elastin in the Structure and Function of Skin. Aesthet Surg J Open Forum. 2021. PMID 34195612
83. Roten SV, Bhat S, Bhawan J. Elastic fibers in scar tissue. J Cutan Pathol. 1996;23:37-42. PMID 8720985
84. Widgerow AD, et al. TriHex Technology and Reversal of Solar Elastosis: Dispelling Some Myths. J Cosmet Dermatol. 2026. PMID 41918136
85. Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007. PMID 17227934
86. US Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. usada.org
87. US FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov, page current as of 22 April 2026
88. US FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
89. US FDA. Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 2026. fda.gov/media/193342/download
90. Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. PMID 20536470
91. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID 16352683
92. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Am J Physiol Endocrinol Metab. 2025. PMID 39679943
93. Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025. PMID 40141333
94. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017. PMID 28266027
95. Langendonk JG, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015. PMID 26132941
96. Nukaly HY, et al. Oral and topical peptides for skin aging: SR and meta-analysis of RCTs. Front Med. 2026;13:1618306. PMID 41924746
97. Roh M, et al. Sebum output as a factor contributing to the size of facial pores. Br J Dermatol. 2006;155:890-4. PMID 17034515
98. Thadanipon K, Kitsongsermthon J. Facial pore evaluation. Skin Res Technol. 2020;26:163-168. PMID 31562649
99. Sugiyama-Nakagiri Y, et al. Involvement of IGFBP-3 in the enlargement of facial pores. Arch Dermatol Res. 2010;302:661-7. PMID 20567839
100. Kim SJ, et al. Evaluation of facial pore severity. Skin Res Technol. 2014;20:429-34. PMID 24645873
101. Park JY, et al. Intradermal Microdroplet Injection of Diluted Incobotulinumtoxin-A for Sebum Control, Face Lifting, and Pore Size Improvement. J Drugs Dermatol. 2021. PMID 33400411
102. Beitner H. Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% alpha-lipoic acid. Br J Dermatol. 2003;149:841-9. PMID 14616378
103. Gold MH, et al. Human growth factor and cytokine skin cream for facial skin rejuvenation. J Drugs Dermatol. 2007. PMID 17966179
104. Randhawa M, et al. Daily Use of a Facial Broad Spectrum Sunscreen Over One-Year Significantly Improves Clinical Evaluation of Photoaging. Dermatol Surg. 2016. PMID 27749441
105. Schmidt JB, et al. Treatment of skin aging with topical estrogens. Int J Dermatol. 1996. PMID 8876303
106. Sharma A, et al. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngol Head Neck Surg. 2025. PMID 40407186
107. Varani J, et al. Decreased collagen production in chronologically aged skin. Am J Pathol. 2006;168:1861-8. PMID 16723701
108. Fisher GJ, et al. Collagen fragmentation promotes oxidative stress and elevates matrix metalloproteinase-1 in fibroblasts in aged human skin. Am J Pathol. 2009;174:101-14. PMID 19116368
109. Renova [tretinoin cream] 0.02% — FDA structured product label, Indications and Usage and Warnings sections. Retrieved via the openFDA drug label API, 21 August 2026

Inside Your Peptides is independent. We sell nothing. We disclose every referral relationship where one exists. The report above contains no vendor link; the sourcing desk that follows it is separate, and disclosed.

This report is for research and educational purposes only. It is not medical advice. Nothing here is a dosing recommendation or a suggestion to obtain, possess or administer any compound. Several substances discussed are unapproved, prescription-only, or subject to active regulatory proceedings. Speak to a qualified clinician before making any decision about your skin or your health.